[go: up one dir, main page]

SE0000855D0 - Antigenic composition useful as a vaccine against atherosclerosis - Google Patents

Antigenic composition useful as a vaccine against atherosclerosis

Info

Publication number
SE0000855D0
SE0000855D0 SE0000855A SE0000855A SE0000855D0 SE 0000855 D0 SE0000855 D0 SE 0000855D0 SE 0000855 A SE0000855 A SE 0000855A SE 0000855 A SE0000855 A SE 0000855A SE 0000855 D0 SE0000855 D0 SE 0000855D0
Authority
SE
Sweden
Prior art keywords
antigenic composition
vaccine against
against atherosclerosis
dialdehyde
tcr
Prior art date
Application number
SE0000855A
Other languages
English (en)
Inventor
Goeran K Hansson
Sten Stemme
Antonio Nicoletti
Dirk Wuttge
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0000855A priority Critical patent/SE0000855D0/sv
Publication of SE0000855D0 publication Critical patent/SE0000855D0/sv
Priority to EP01916008A priority patent/EP1335742B1/en
Priority to PCT/SE2001/000570 priority patent/WO2001068119A1/en
Priority to DE60135010T priority patent/DE60135010D1/de
Priority to AT01916008T priority patent/ATE401907T1/de
Priority to US10/221,573 priority patent/US20040002111A1/en
Priority to AU2001242952A priority patent/AU2001242952A1/en
Priority to DK01916008T priority patent/DK1335742T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0000855A 2000-03-15 2000-03-15 Antigenic composition useful as a vaccine against atherosclerosis SE0000855D0 (sv)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SE0000855A SE0000855D0 (sv) 2000-03-15 2000-03-15 Antigenic composition useful as a vaccine against atherosclerosis
EP01916008A EP1335742B1 (en) 2000-03-15 2001-03-15 Use of peptides dervied from apoB100 in the production of a vaccine/diagnostic against atherosclerosis
PCT/SE2001/000570 WO2001068119A1 (en) 2000-03-15 2001-03-15 Atherosclerosis vaccine
DE60135010T DE60135010D1 (de) 2000-03-15 2001-03-15 Verwendung von apoB100 Peptidderivaten zur Herstellung eines Impfstoffs/Diagnose gegen Atherosklerose
AT01916008T ATE401907T1 (de) 2000-03-15 2001-03-15 Verwendung von apob100 peptidderivaten zur herstellung eines impfstoffs/diagnose gegen atherosklerose
US10/221,573 US20040002111A1 (en) 2000-03-15 2001-03-15 Atherosclerosis vaccine
AU2001242952A AU2001242952A1 (en) 2000-03-15 2001-03-15 Atherosclerosis vaccine
DK01916008T DK1335742T3 (da) 2000-03-15 2001-03-15 Anvendelse af peptider afledt af apoB100 til fremstilling af en vaccine/et diagnostisk middel mod atherosclerose

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000855A SE0000855D0 (sv) 2000-03-15 2000-03-15 Antigenic composition useful as a vaccine against atherosclerosis

Publications (1)

Publication Number Publication Date
SE0000855D0 true SE0000855D0 (sv) 2000-03-15

Family

ID=20278814

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000855A SE0000855D0 (sv) 2000-03-15 2000-03-15 Antigenic composition useful as a vaccine against atherosclerosis

Country Status (8)

Country Link
US (1) US20040002111A1 (sv)
EP (1) EP1335742B1 (sv)
AT (1) ATE401907T1 (sv)
AU (1) AU2001242952A1 (sv)
DE (1) DE60135010D1 (sv)
DK (1) DK1335742T3 (sv)
SE (1) SE0000855D0 (sv)
WO (1) WO2001068119A1 (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279459B2 (en) 2001-01-04 2007-10-09 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US8119590B2 (en) 2001-09-28 2012-02-21 Cedars-Sinai Medical Center Prevention and treatment of restenosis by local administration of drug
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
US8012483B2 (en) * 2004-04-15 2011-09-06 Athera Biotechnologies Ab Phosphorylcholine conjugates and corresponding antibodies
EP2281007B1 (en) 2008-04-10 2014-07-09 Thrombosis Research Institute Anti-atheroma vaccine
US8609605B2 (en) 2009-03-17 2013-12-17 Cardiovax, Llc Immunomodulatory methods for treatment of atherosclerosis via inhibition of CD4+ T cell response to APOB100
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
US9125850B2 (en) * 2009-11-14 2015-09-08 Cardio Vax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
CA2813268A1 (en) * 2010-09-22 2012-03-29 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
AU2011325946A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
WO2013022968A1 (en) 2011-08-09 2013-02-14 Athera Biotechnologies Ab Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
KR101947758B1 (ko) 2011-08-09 2019-02-14 아테라 바이오테크놀로지스 아베 포스포릴콜린에 대한 신규 항체
EP3484284A1 (en) * 2016-07-12 2019-05-22 Kymab Limited Animals, cells, ligands, polypeptides & methods
WO2018236909A1 (en) * 2017-06-20 2018-12-27 La Jolla Institute For Allergy And Immunology Engineered t-cell receptors and methods of their use in modulating inflammatory responses and treating atherosclerosis
WO2023240120A2 (en) * 2022-06-07 2023-12-14 La Jolla Institute For Immunology Novel treatments for cardiovascular related disease

Also Published As

Publication number Publication date
US20040002111A1 (en) 2004-01-01
ATE401907T1 (de) 2008-08-15
AU2001242952A1 (en) 2001-09-24
WO2001068119A1 (en) 2001-09-20
DK1335742T3 (da) 2008-11-17
DE60135010D1 (de) 2008-09-04
EP1335742A1 (en) 2003-08-20
EP1335742B1 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
SE0000855D0 (sv) Antigenic composition useful as a vaccine against atherosclerosis
WO1995029193A3 (en) Melanoma antigens
EP0677533A3 (en) Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT990044E (pt) Metodo para evolucao molecular in vitro da funcao de proteinas
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
ATE153695T1 (de) Verfahren zur herstellung von antikörpern
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
WO2007120834A3 (en) Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
RU2011138060A (ru) Средства и способы получения высокоочищенного нейротоксина
DE69233366D1 (de) Antigene, die von Polyarthritis Rheumatoide Antikörpern erkannt werden, ihre Herstellung und ihre Anwendungen
DE69114339T2 (de) Verfahren zur Identifizierung oder Bestimmung von Proteinen und Verwendungen dazu.
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
WO1999058678A3 (en) Antibodies to dendritic cells and human dendritic cell populations and uses thereof
WO2002008716A3 (fr) Procede de criblage de peptides utilisables en immunotherapie
WO1999013907A3 (en) Methods to improve immunogenicity of antigens and specificity of antibodies
ES534510A0 (es) Un metodo para determinar la presencia de una secuencia natural de restos aminoacidos de un protenoide.
JPS6470498A (en) Synthetic peptide and antibody thereto
Rüdiger et al. Monoclonal antibody ID5: epitope characterization and minimal requirements for the recognition of polyglutamylated α-and β-tubulin
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
DK1374895T3 (da) Farmaceutisk sammensætning af F(AB) 2-fragmenter af antistoffer og fremgangsmåde til fremstilling heraf
DE69836024D1 (de) Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga-vermittelten immunantwort
EP1094080A3 (en) Anti-dnase-gamma antibody, and production and use thereof
EP0806478A3 (en) p53as Protein and antibody therefor
KR910005887A (ko) 면역원성 물질의 고-보존된 아미노산 서열에 대한 항체, 이의 항체의 제조 방법 및 면역 감정에서의 이의 용도